Regorafenib dose-optimisation in patients with refractory metastatic colorectal cancer (ReDOS): a randomised, multicentre, open-label, phase 2 study

Tanios S. Bekaii-Saab, Fang Shu Ou, Daniel H. Ahn, Patrick M. Boland, Kristen K. Ciombor, Erica N. Heying, Travis J. Dockter, Nisha L. Jacobs, Boris C. Pasche, James M. Cleary, Jeffrey P. Meyers, Rodwige J. Desnoyers, Jeannine S. McCune, Katrina Pedersen, Afsaneh Barzi, E. Gabriela Chiorean, Jeffrey Sloan, Mario E. Lacouture, Heinz Josef Lenz, Axel Grothey

Research output: Contribution to journalArticlepeer-review

109 Scopus citations

Fingerprint

Dive into the research topics of 'Regorafenib dose-optimisation in patients with refractory metastatic colorectal cancer (ReDOS): a randomised, multicentre, open-label, phase 2 study'. Together they form a unique fingerprint.

Medicine & Life Sciences